Rheumatology Search
Rheumatology Rheumatology
Most Read Articles
Ofatumumab a safe, effective alternative in B cell–depletion therapy
5 days ago
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
Herpes zoster vaccine may be used in RA patients receiving cDMARD, low-dose GC
13 Apr 2018
A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).
Infliximab superior to TNFi in treatment of patients with ankylosing spondylitis
15 Apr 2018
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.

Podcast: Dr Fen Lee Hew talks about the pressing need to prevent osteoporotic fractures in Asia

13 Oct 2017
Podcast: Dr Fen Lee Hew talks about the pressing need to prevent osteoporotic fractures in Asia
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Ofatumumab a safe, effective alternative in B cell–depletion therapy
5 days ago
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
Herpes zoster vaccine may be used in RA patients receiving cDMARD, low-dose GC
13 Apr 2018
A recent study has shown that the herpes zoster (HZ) vaccine induces varicella zoster virus (VZV)-specific cellular and humoral responses in patients with rheumatic arthritis (RA).
Infliximab superior to TNFi in treatment of patients with ankylosing spondylitis
15 Apr 2018
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.